Avacta Share Discussion Threads

[lantanatony] 16/11/2017 13:00

All sellers today so much for yesterday's presentation to shareholders!

[lantanatony] 16/11/2017 12:58

All sellers today so much for yesterday's presentation to shareholders!

[lantanatony] 13/11/2017 10:11

Sorry ,I can't make Wednesday
Anyone who is going please ask for some feed back from the market.
As for Finncap,in my mind their time has come an gone.
There is little or no support from them for the shares and I don't believe they have the ability to retain the confidence of the substantial shareholders.
Avacta's corporate story is getting stale and without any further positive reaction from the market,what is the point of these Retail shareholder presentations?

[the drewster] 11/11/2017 07:55

Anyone going on Wednesday?

[lantanatony] 08/11/2017 20:54

No support from for the share price from the market or our Brokers even at this low share price.
Meanwhile, there seems to be at least one substantial seller about.
Therefore, what is the point of our CEO presenting at a Finncap event this month when the hosts are not convinced?
I have to ask, what party is insisting on the confidentiality in the deals that Avacta have published?
Could it be Avacta are wanting to hide from the deal detail?!
Can the whole Big Pharma investing sector be wrong to ignore Avacta?
The share price says it all.

[dj56] 03/11/2017 17:19

Reading this discussion, it seems that Avacta has bought a lot of different early stage technologies over the years that have not really worked out. They now seem to be back filling with "Affimers" as the latest throw of the dice, which is a big ask I suspect. Two years away from the clinic and not enough cash to get there is a real worry. The current revenue projections are not exciting and the company seems to be run as a series of academic projects. Not one for me, I'm afraid.

[dj56] 03/11/2017 17:06

Reading this discussion, it seems that Avacta has bought a lot of different early stage technologies over the years that have not really worked out. They now seem to be back filling with "Affimers" as the latest throw of the dice, which is a big ask I suspect. Two years away from the clinic and not enough cash to get there is a real worry. The current revenue projections are not exciting and the company seems to be run as a series of academic projects. Not one for me........

[mj747] 30/10/2017 08:45

MrAngry2,
I've been looking to invest in a phage display technology platform company like Avacta and there are quite a few to choose from. The technology seems sound and backed by peer-reviewed publications but commercial traction seems to have been slow compared with other companies out there. Prof Smith has strong track record as an academic physicist but this is his first attempt at anything commercial. From the videos he seems very enthusiastic and engaging fellow but the strategy seems to be a bit of a scatter-gun approach: let's try everything all at once! I'm a patient investor like you but this Company looks like a typical academic start up. Have I missed anything here? I see you have all been following this company for years. Many thanks for your advice.

[mrangry2] 27/10/2017 11:52

How can you expect a life science company to produce revenue without doing years and years of research? That's the way things are I'm afraid.
If you haven't got the patience for that, then I suggest you invest elsewhere.

[lantanatony] 26/10/2017 22:16

Shares down again today!
With no support from our Market Marketer's .


Therefore,
Perhaps Alistair Smith should stop
doing these meaningless investor presentations and get on with producing some meaningful revenue.
Bonzo is correct,
The management at Avacta need to get on with it or butt out!
They have had plenty of time.

In my view our main shareholder is the problem.....IP Group .

It seems they have overloaded Avacta with loads of questionable stuff....
Long term investors have been subjected to dilution on many occasions because of this.

The Avacta CEO may be Ok,but the rest of the Board seem to be poor.
Avacta keep making allsorts of appointments to the Board and their key staff
but it seems none of these appointments bring a anything to the revenue stream.

Have an in-depth look at IP Group,just consider what they have transferred into Avacta over time,You may be Surprised to find just how many millions of their VALUE
that turns out to be!

[poacher45] 24/10/2017 16:13

Bonzo Lets say they are very well paid management in my opinion performing very badly.

[wan] 24/10/2017 15:53

Too many missed targets/goals to list, year after year! Collaborations that come to nothing, plus the strategy has changed more times than I care to remember.

Interesting to learn that there will indeed be another fund raise, which some said would not be required. Same old story, over and over again!

[bonzo] 24/10/2017 14:47

Poacher are you suggesting that badly paid management performs better than well paid management? Which is more likely to succeed? Bsdly paid management or well paid management? The management costs are small compared with the cost of running the business... pay them well and make them deliver!

[lantanatony] 24/10/2017 14:30

Poacher45 has his view,others may differ.
But one thing is for sure Therapeutics is a big boys game!
Management and the right financial support are key even if you get very lucky.
Finncap and the like wont get Avacta into the true therapeutic space.
They need a deal with a significant player then the shares will move.
Be lucky.

[poacher45] 24/10/2017 13:54

E1nstein you just keep taking the rights issues up. My point is the company has failed to make a commercial success of any project so far and nothing convinces me that this is going to be any different. Wan tried for ages to promote this company and he gave up after all the failures. To me the money is not going in R and D but ending up in high salaries to management. I may be wrong I hope I am I want British companies to succeed but to me this is just a badly run company.

[e1nstein] 24/10/2017 11:29

Poacher45 - others have responded to you on this point before but just to say it again - when Avacta bought the Affimer IP in 2012 the strategy changed and the company focused on Affimers because that is a much bigger opportunity and they sold one revenue generating part of the business so it makes no sense to talk about a strategy that changed five years ago. In my opinion Affimers is a growth story and if you want the upside of Affimer therapeutics then R&D investment (or overheads as you call it) needs to be significant and that is what money was raised for in 2015. I have never heard anyone else talk about profit in relation to an early stage biotech platform.

[poacher45] 24/10/2017 10:44

When is it going to make a profit? From memory I think Alistair forecast a profit in 2012 but several projects have bit the dust since then. Every time it is the same story ever increasing overheads jam tomorrow but tomorrow never comes.

[timbo003] 24/10/2017 09:40

Avacta were at the Shares Magazine Investor seminar last Thursday, with Alistair Smith (CEO) giving the presentation, some good Q&As at the end too (see link to video below):


I think affirmers are a very neat idea and seem to do the same job as monoclonals (but offer the opportunity to be simpler, faster and more adaptable in many cases). The reagent side certainly looks as if it could become a viable business, without much more investment, although the therapeutics side is very early stage and is likely to gobble cash for some time to come.

When I talked to Alistair afterward the meeting, I managed to glean a few more factoids:


* They have raised a total of around £40m - 50 m from shareholders so far, i.e. the same level as the market cap. Unfortunately, they no longer qualify for EIS funding, they will need more funding (obviously) and Alistair seemed to be very interested in using Primary Bid for funding rounds in the future.

* The therapeutic side of the business is very early stage and will be cash hungry, the reagent side is almost at a stage where it could stand alone without further funding.

* I asked about the broker valuations. The broker is Finncap (you can get those from Research Tree). Alistair said that the broker has valued the reagent side of the business to be the same (roughly) as the market cap, so the therapeutic side is in for free (sort of).

* Ultimately they see splitting the business as a possible (and attractive) way forward, whereby existing shareholders would have shares in each new component company.


I like this company its technology and the management, but I will wait to see if there is another share offer in the coming months where Primary Bid get involved and use that as the catalyst for a decision to invest.

[e1nstein] 20/10/2017 16:38

The company are holding a private shareholder event to present the prelim results. The RNS is on the web site but I dont think I saw it when it came out yesterday. Sign up.

In response to The Drewster - Matt Johnson's presentation in San Diego last week is on the web site - second one down in the company presentations list. Confusing since the first one was obviously also at San Diego but in June. Prelim presentation also there higher up the list.

RNS:

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, will be hosting a Private Shareholder event on Wednesday, 15 November 2017 at 2.00 pm until 4.00 pm at finnCap's offices, 60 New Broad St, London EC2M 1JJ and will take the form of a Company presentation to update shareholders on progress followed by a Q&A session.

The presentation for the event will also be made available on the Company's website.

Investors and shareholders who wish to attend the event should register their interest at: [e-mail].

[the drewster] 18/10/2017 17:20

presentations section has some new stuff, but not the one from this month (I have it if anyone wants to PM me with contact details)

[lantanatony] 18/10/2017 10:16

Drewster
Thanks for the head's up.
However,while the market continues to ignore Avacta,we are in the hands of the market maker's.
Unfortunately they don't seem convinced.
Mr Smith has some work to do!

[the drewster] 16/10/2017 09:27

I was at a medical research conference this weekend, and several researchers were genuinely excited at the Affimer benefits ... difficult to prise any specifics out of them, but promising.

[contact2fsnetcouk] 13/10/2017 19:49

TD

A well placed "the" in your comment otherwise, it would have read "on the cusp of the chart breaking downtrend".

:-)

[mrangry2] 13/10/2017 13:53

Sorry, you should have gone! :-)